ArticleFuture oncology (London, England)2015
Development of PROSTVAC immunotherapy in prostate cancer.
Article in Future oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.Journal for immunotherapy of cancer · 2021Trial
- Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions.Vaccines · 2026Review
- Cancer Vaccines: Mechanisms, Clinical Applications, Challenges, and Future Directions in Precision Medicine.Current cancer drug targets · 2026Review
- CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives.Biomedicines · 2025Review
- Strategic Advances in Targeted Delivery Carriers for Therapeutic Cancer Vaccines.International journal of molecular sciences · 2025Review
- Targeted and immunotherapeutic strategies for castration-resistant prostate cancer: emerging strategies, challenges, and future directions.Frontiers in immunology · 2025Review
- Review
- Prophylactic and therapeutic vaccine development: advancements and challenges.Molecular biomedicine · 2024Review
- Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers.Nature reviews. Urology · 2024Review
- Current status and progress of the development of prostate cancer vaccines.Journal of Cancer · 2023Review
- Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.Molecules (Basel, Switzerland) · 2022Review
- Prostate cancer.Nature reviews. Disease primers · 2021Review
- Review
- Development of oncolytic virotherapy: from genetic modification to combination therapy.Frontiers of medicine · 2020Review
- Systematically understanding the immunity leading to CRPC progression.PLoS computational biology · 2019Article
- The Tumor Immune Contexture of Prostate Cancer.Frontiers in immunology · 2019Review
- The molecular biology of prostate cancer: current understanding and clinical implications.Prostate cancer and prostatic diseases · 2018Review
- Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4Journal of virology · 2017Article
- Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.Human vaccines & immunotherapeutics · 2017Article
- PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.Journal of hematology & oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.